NCT05271604 - A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2022

Primary Completion Date

September 22, 2025

Study Completion Date

September 22, 2025

Conditions

Head and Neck CancerSquamous Cell Carcinoma of Head and NeckRecurrent Squamous Cell Carcinoma of the Head and NeckMetastatic CancerMetastatic Squamous Cell Carcinoma of the Head and Neck

Interventions

BIOLOGICAL

Ozuriftamab Vedotin

Conditionally active biologic anti-ROR2 antibody drug conjugate

BIOLOGICAL

Pembrolizumab

PD-1 inhibitor

BIOLOGICAL

Evalstotug (BA3071)

Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody

BIOLOGICAL

Cetuximab

Epidermal growth factor receptor (EGFR) antagonist

Trial Locations (7)

10065

Memorial Sloan-Kettering Cancer Center, New York

19713

Christiana Care Helen Graham Cancer Center, Newark

40202

Norton Cancer Institute, Louisville

60611

Northwestern University, Chicago

63110

Washington University Medical Siteman Cancer Center, St Louis

84112

Huntsman Cancer Institute, Salt Lake City

90033

USC Norris Comprehensive Cancer Center, Los Angeles